Two Sigma Investments LP Sells 79,346 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Two Sigma Investments LP trimmed its holdings in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 43.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 105,227 shares of the company's stock after selling 79,346 shares during the period. Two Sigma Investments LP owned 0.21% of Cardiff Oncology worth $457,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in Cardiff Oncology by 68.7% during the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock worth $1,253,000 after acquiring an additional 117,514 shares during the period. Nuveen Asset Management LLC boosted its position in shares of Cardiff Oncology by 73.7% in the 4th quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company's stock worth $2,546,000 after purchasing an additional 248,850 shares during the last quarter. Laurion Capital Management LP acquired a new stake in shares of Cardiff Oncology during the fourth quarter worth $2,504,000. American Century Companies Inc. increased its holdings in Cardiff Oncology by 12.8% in the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock valued at $234,000 after purchasing an additional 6,140 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Cardiff Oncology by 8.9% in the fourth quarter. Northern Trust Corp now owns 337,092 shares of the company's stock valued at $1,463,000 after buying an additional 27,489 shares during the period. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Trading Up 11.4%

Shares of CRDF stock traded up $0.44 on Tuesday, hitting $4.30. The stock had a trading volume of 1,857,462 shares, compared to its average volume of 1,158,687. Cardiff Oncology, Inc. has a twelve month low of $2.01 and a twelve month high of $5.64. The company has a fifty day moving average price of $2.91 and a two-hundred day moving average price of $3.49. The firm has a market cap of $286.06 million, a P/E ratio of -4.57 and a beta of 1.61.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.09 million. On average, analysts expect that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their target price on Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, May 9th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.